Jim Simons Day One Biopharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 348,440 shares of DAWN stock, worth $2.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

348,440

Previous 243,740 42.96%

Holding current value

$2.31 Million

Previous $3.09 Million 10.52%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$7.93 - $13.21 $830,271 - $1.38 Million	104,700 Added 42.96%	348,440 $2.76 Million
Q4 2024 Feb 13, 2025	BUY	$12.46 - $16.39 $1.86 Million - $2.44 Million	148,900 Added 157.0%	243,740 $3.09 Million
Q3 2024 Nov 13, 2024	BUY	$12.72 - $16.03 $288,744 - $363,881	22,700 Added 31.47%	94,840 $1.32 Million
Q2 2024 Aug 09, 2024	BUY	$12.03 - $17.69 $867,844 - $1.28 Million	72,140 New	72,140 $994,000
Q2 2023 Aug 11, 2023	SELL	$11.74 - $14.47 $2.82 Million - $3.47 Million	-239,936 Reduced 63.29%	139,164 $1.66 Million
Q1 2023 May 12, 2023	BUY	$12.75 - $23.41 $2.95 Million - $5.42 Million	231,674 Added 157.15%	379,100 $5.07 Million
Q4 2022 Feb 13, 2023	BUY	$18.77 - $22.0 $929,603 - $1.09 Million	49,526 Added 50.59%	147,426 $3.17 Million
Q3 2022 Nov 14, 2022	SELL	$16.44 - $26.57 $307,921 - $497,656	-18,730 Reduced 16.06%	97,900 $1.96 Million
Q2 2022 Aug 12, 2022	BUY	$5.72 - $17.9 $667,123 - $2.09 Million	116,630 New	116,630 $2.09 Million

Others Institutions Holding DAWN

# of Institutions

196

Shares Held

76.7M

Call Options Held

138K

Put Options Held

208K

View Full List

About Day One Biopharmaceuticals, Inc.

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $488M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

More about DAWN

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account